Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.

Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. However, no head to head trials between these TKIs in mutated popula...

Full description

Bibliographic Details
Main Authors: Wenhua Liang, Xuan Wu, Wenfeng Fang, Yuanyuan Zhao, Yunpeng Yang, Zhihuang Hu, Cong Xue, Jing Zhang, Jianwei Zhang, Yuxiang Ma, Ting Zhou, Yue Yan, Xue Hou, Tao Qin, Xiaoxiao Dinglin, Ying Tian, Peiyu Huang, Yan Huang, Hongyun Zhao, Li Zhang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3922700?pdf=render

Internet

http://europepmc.org/articles/PMC3922700?pdf=render

Similar Items